<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1288</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15190071</PubmedId>
            <Abstract>The solution structure of domain III from the New York West Nile virus strain 385-99 (WN-rED3) has been determined by NMR methods. The West Nile domain III structure is a beta-barrel structure formed from seven anti-parallel beta-strands in two beta-sheets. One anti-parallel beta-sheet consists of beta-strands beta1 (Phe(299)-Asp(307)), beta2 (Val(313)-Tyr(319)), beta4 (Arg(354)-Leu(355)), and beta5 (Lys(370)-Glu(376)) arranged so that beta2 is flanked on either side by beta1 and beta5. The short beta4 flanks the end of the remaining side of beta5. The remaining anti-parallel beta-sheet is formed from strands beta3 (Ile(340)-Val(343)), beta6 (Gly(380)-Arg(388)), and beta7 (Gln(391)-Lys(399)) arranged with beta6 at the center. Residues implicated in antigenic differences between different West Nile virus strains (and other flaviviruses) and neutralization are located on the outer surface of the protein. Characterization of the binding of monoclonal antibodies to WN-rED3 mutants, which were identified through neutralization escape experiments, indicate that antibody neutralization directly correlates with binding affinities. These studies provide an insight into theoretical virus-receptor interaction points, structure of immunogenic determinants, and potential targets for antiviral agents against West Nile virus and highlight differences between West Nile virus and other flavivirus structures that may represent critical determinants of virulence.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>38755-61</ArticlePages>
            <ArticleTitle>Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Volk</LastName>
                    <ForeName>David E</ForeName>
                </Author>
                <Author>
                    <LastName>Beasley</LastName>
                    <ForeName>David W C</ForeName>
                </Author>
                <Author>
                    <LastName>Kallick</LastName>
                    <ForeName>Deborah A</ForeName>
                </Author>
                <Author>
                    <LastName>Holbrook</LastName>
                    <ForeName>Michael R</ForeName>
                </Author>
                <Author>
                    <LastName>Barrett</LastName>
                    <ForeName>Alan D T</ForeName>
                </Author>
                <Author>
                    <LastName>Gorenstein</LastName>
                    <ForeName>David G</ForeName>
                </Author>
            </Authors>
            <Affiliations>Sealy Center for Structural Biology, University of Texas Medical Branch, Galveston, Texas 77555-1147, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Viral Envelope Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antibodies, Monoclonal(chemistry); Magnetic Resonance Spectroscopy; Models, Molecular; Mutation; Protein Binding; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Viral Envelope Proteins(chemistry); West Nile virus(metabolism; pathogenicity)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>279</Volume>
                <Issue>37</Issue>
                <Title>The Journal of biological chemistry</Title>
                <Issn>1083-351X</Issn>
                <MedlineTa>J Biol Chem</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Domain III of E glycoprotein</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>K307, T330</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>AAK58102.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>307044</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>76999</EpitopeId>
                <ReferenceRegion>K307, T330</ReferenceRegion>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>19010</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs used in this study were obtained from Bioreliance and were generated against WNV strain NY99.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Three mAbs 5H210, 5C5, and 3A3 had similar neutralization indices against the wild-type strain of virus.  mAbs 5H10 and 3A3 both showed 2 -3 log&lt;sub&gt;10&lt;/sub&gt; units reduction in neutralization of escape mutants.  mAb 5C5 retained a neutralization index similar to the wild-type index against the T330I escape mutant.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 5H10, 5C5, 3A3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Wild-type West Nile Virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>307044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>19009</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000971</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>mAbs used in this study were obtained from Bioreliance and were generated against WNV strain NY99.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A comparison of mAb binding curves to West-Nile Virus WN-rED3 and mutants at positions K307, T330 was performed.  Calculated K&lt;sub&gt;d&lt;/sub&gt; values for all mAbs were comparable, ranging between 0.1-0.2 nM.  Differential binding responses to each mutation were also compared at 100 nM antigen.  Binding by mAbs 5H10 and 3A3 to mutants was nearly abolished as compared to wild-type binding. mAb 7H2 did not lose significant reactivity in either mutant.  Binding of mAb 5C5 was abolished in the K370 mutant, but only reduced in the T330 mutant indicating a difference in fine specificity.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 5H10, 5C5, 3A3</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>rED3 (L297-S403) Fusion protein</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LKGTTYGVCSKAFKFLGTPADTGHGTVVLELQYTGTDGPCKVPISSVASLNDLTPVGRLVTVNPFVSVATANAKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSS</LinearSequence>
                                        <StartingPosition>297</StartingPosition>
                                        <EndingPosition>403</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAK58102.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>307044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

